THE ANALYSIS OF NEW DRUG REIMBURSEMENT DECISION MAKING IN SOUTH KOREA AFTER THE INTRODUCTION OF POSITIVE LISTING SYSTEM

被引：1
|
作者：
Kim, S. [1 ]
Cho, H. [1 ]
Yoo, H. [2 ]
Cho, J. [3 ]
Kang, K. [4 ]
Kim, J. [5 ]
机构：
[1] Novartis Korea, Seoul, South Korea
[2] AstraZeneca Korea, Seoul, South Korea
[3] Lilly Korea, Seoul, South Korea
[4] Abbvie Korea, Seoul, South Korea
[5] Ipsen Korea, Seoul, South Korea
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1670
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP138
引用
收藏
页码：A676 / A676
页数：1
相关论文
共 50 条
  • [21] Are Recently Evaluated Drugs More Likely to Receive Positive Reimbursement Recommendations in South Korea? 11-year Experience of the South Korean Positive List System
    Gong, Ji Ryoun
    Lee, Donghwan
    Lim, Kyung-Min
    Bae, SeungJin
    [J]. CLINICAL THERAPEUTICS, 2020, 42 (07) : 1222 - 1233
  • [22] Reimbursement Coverage Decision Making for Digital Health Technologies in South Korea: Does It Fit the Value Framework Used in Traditional Medical Technologies?
    Myung, Jae-Eun
    Strachan, Liesl
    Shin, Jaeyong
    Yim, Jaejun
    Lee, Sang-Soo
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 27 - 33
  • [23] Perceptions of Regulatory Decision-Making for New Drugs From the Viewpoints of the Manufacturers in South Korea
    Son, Kyung-Bok
    Park, Sylvia
    [J]. FRONTIERS IN MEDICINE, 2022, 9
  • [24] Variables affecting new drug prices in South Korea's pricing system
    Lee, Dong Yun
    Cho, Seong Ha
    Lee, Da Hye
    Kang, Su Jeong
    Lee, Jong Hyuk
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] PRACTICAL PROBLEMS OF COMPARATOR SELECTION TO ASSESS COST-EFFECTIVENESS OF NEW DRUGS FOR REIMBURSEMENT DECISION: A QUALITATIVE STUDY IN SOUTH KOREA
    Kang, H.
    Lee, H.
    Cho, H.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A96 - A96
  • [26] A Comparative Analysis of the Impact of a Positive List System on New Chemical Entity Drugs and Incrementally Modified Drugs in South Korea
    Ha, DongMun
    Choi, Yong
    Kim, Dae Up
    Chung, Kyu Hyuck
    Lee, Eui-Kyung
    [J]. CLINICAL THERAPEUTICS, 2011, 33 (07) : 926 - 932
  • [27] A study on analysis of clinical efficacy factor and exploring prognostic factors for reimbursement policy after immunotherapy being introduced in South Korea
    Yi, J.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 32 - 32
  • [28] Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System
    Yoo, Seung-Lai
    Kim, Dae-Jung
    Lee, Seung-Mi
    Kang, Won-Gu
    Kim, Sang-Yoon
    Lee, Jong Hyuk
    Suh, Dong-Churl
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2019, 16 (02)
  • [29] Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years
    Kim, Sungju
    Kim, Jinhong
    Cho, Hyunyoung
    Lee, Kyungmin
    Ryu, Chiyoung
    Lee, Jong Hyuk
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 477 - 486
  • [30] Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions
    Carlos King Ho Wong
    Olivia Wu
    Bernard M. Y. Cheung
    [J]. Applied Health Economics and Health Policy, 2018, 16 : 5 - 14
12345